My take is this is seperate to the SubB2M program. EXO-NET is a platform technology used for isolating the relevant exosomes from the sample in question i.e., blood sample from a potential / suspected ovarian cancer patient. The assay UQ will be develop will to detect the relevant exosome marker in question.
Please also note that releasing news of signing a CRO for the SubB2M program is also no guarantee. Will they tech transfer a test developed in the iNOVIQ lab (ELISA / IHC) and if so, optimisation, validation and test readiness under a NATA / CAP accredited lab will need to be completed in roughly 12 - 18 months if we are to see an LDT launch in 2023. Importantly, are they manufacturing a research grade SubB2M product in the meantime in order to provide to the CRO to test in the developed assay?
- Forums
- ASX - By Stock
- IIQ
- Ann: INOVIQ & UQ Collaborate on Exosome-based Ovarian Cancer Test
Ann: INOVIQ & UQ Collaborate on Exosome-based Ovarian Cancer Test, page-19
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IIQ (ASX) to my watchlist
|
|||||
Last
55.0¢ |
Change
0.005(0.92%) |
Mkt cap ! $60.92M |
Open | High | Low | Value | Volume |
56.5¢ | 56.5¢ | 55.0¢ | $15.12K | 26.91K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 13918 | 55.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
56.0¢ | 15000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 13918 | 0.550 |
2 | 15062 | 0.545 |
4 | 29113 | 0.540 |
1 | 10000 | 0.535 |
2 | 5000 | 0.530 |
Price($) | Vol. | No. |
---|---|---|
0.560 | 15000 | 1 |
0.570 | 26027 | 2 |
0.585 | 10000 | 1 |
0.590 | 5000 | 1 |
0.595 | 10000 | 1 |
Last trade - 15.16pm 06/09/2024 (20 minute delay) ? |
Featured News
IIQ (ASX) Chart |